A modified chromogenic assay for the measurement of very low levels of factor VIII activity (FVIII:C)

被引：8

作者：

Yatuv, R ^{[1
]}

Dayan, I ^{[1
]}

Baru, M ^{[1
]}

机构：

[1] Omri Labs Ltd, IL-76106 Rehovot, Israel

来源：

HAEMOPHILIA | 2006年 / 12卷 / 03期

关键词：

chromogenic assay; factor VIII; haemophilia A;

D O I：

10.1111/j.1365-2516.2006.01209.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

A precise and sensitive chromogenic assay for the measurement of very low levels of factor VIII (FVIII) in plasma has been developed. The assay is based on modifications of a commercially available chromogenic assay. The modifications include reduction of sample final dilution factor and prolongation of the development period. The modified assay allows accurate and precise measurement of FVIII in the range of 0.001-0.02 IU mL(-1). The detection limit is 0.0005 IU mL(-1) and the quantitation limit is 0.0015 IU mL(-1). This assay can be used in research and to study the clinical efficacy of low circulating levels of FVIII in haemophilia A patients.

引用

收藏

页码：253 / 257

页数：5

相关论文

共 12 条

[1] Monitoring haemophilia severity and treatment: new or old laboratory tests? [J].

Barrowcliffe, TW .

HAEMOPHILIA, 2004, 10 :109-114

[2] Factor VIII efficient and specific non-covalent binding to PEGylated liposomes enables prolongation of its circulation time and haemostatic efficacy [J].

Baru, M ;

Carmel-Goren, L ;

Barenholz, Y ;

Dayan, I ;

Ostropolets, S ;

Slepoy, I ;

Gvirtzer, N ;

Fukson, V ;

Spira, J .

THROMBOSIS AND HAEMOSTASIS, 2005, 93 (06) :1061-1068

[3] Thrombin generation and phenotypic correlation in haemophilia A [J].

Beltrán-Miranda, CP ;

Khan, A ;

Jaloma-Cruz, AR ;

Laffan, MA .

HAEMOPHILIA, 2005, 11 (04) :326-334

[4]

ICH, 1996, INT C HARM TECHN REQ

[5] Potential role of the dynamic properties of whole blood coagulation in assessment of dosage requirements in haemophilia [J].

Ingerslev, J ;

Poulsen, LH ;

Sorensen, B .

HAEMOPHILIA, 2003, 9 (04) :348-352

[6] AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B [J].

Manno, CS ;

Chew, AJ ;

Hutchison, S ;

Larson, PJ ;

Herzog, RW ;

Arruda, VP ;

Tai, SJ ;

Ragni, MV ;

Thompson, A ;

Ozelo, M ;

Couto, LB ;

Leonard, DGB ;

Johnson, FA ;

McClelland, A ;

Scallan, C ;

Skarsgard, E ;

Flake, AW ;

Kay, MA ;

High, KA ;

Glader, B .

BLOOD, 2003, 101 (08) :2963-2972

[7] A modified thrombin generation test for the measurement of factor VIII concentrates [J].

Mcintosh, JH ;

Owens, D ;

Lee, CA ;

Raut, S ;

Barrowcliffe, TW .

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2003, 1 (05) :1005-1011

[8]

OVER J, 1984, SCAND J HAEMATOL, V33, P13

[9] What factors should influence the dosage and interval of prophylactic treatment in patients with severe haemophilia A and B? [J].

Petrini, P .

HAEMOPHILIA, 2001, 7 (01) :99-102

[10]

ROSEN S, 1985, THROMB HAEMOSTASIS, V54, P818